# TITAN (NCT02489318)

> A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

No report yet. It can be ordered.

- Drugs tested: apalutamide
- Indication: metastatic hormone-sensitive prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02489318
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Aragon Pharmaceuticals, Inc.
- Conditions: Prostate Cancer
- Interventions: Apalutamide; Placebo; Androgen Deprivation Therapy (ADT)
- Enrollment: 1052
- Primary outcome: Radiographic Progression-free Survival (rPFS)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on TITAN so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=titan-nct02489318